Recent Finacing
Recent Raise
Apexigen is a clinical-stage biopharma developing antibody therapeutics via its APXiMAB discovery platform; its CD40 agonist monoclonal APX005M is in multiple Phase 2 trials for solid tumors.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
